DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS)
CNY 17.05
(-1.56%)
CNY 17.05
(-1.56%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.59 Billion CNY | 24.38% |
| 2022 | 2.75 Billion CNY | 16.46% |
| 2021 | 2.64 Billion CNY | 44.78% |
| 2020 | 1.82 Billion CNY | 49.2% |
| 2019 | 1.26 Billion CNY | 27.26% |
| 2018 | 1 Billion CNY | 16.87% |
| 2017 | 730.73 Million CNY | 13.94% |
| 2016 | 655.27 Million CNY | 6.27% |
| 2015 | 680.19 Million CNY | 25.55% |
| 2014 | 541.7 Million CNY | 41.11% |
| 2013 | 342.76 Million CNY | 30.35% |
| 2012 | 263.76 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 815.18 Million CNY | 23.72% |
| 2024 Q1 | 643.06 Million CNY | 46.39% |
| 2024 Q3 | 330.21 Million CNY | -61.01% |
| 2023 Q4 | 467.64 Million CNY | 9.01% |
| 2023 Q1 | 766.35 Million CNY | 1190.6% |
| 2023 Q2 | 599.95 Million CNY | -21.71% |
| 2023 FY | - CNY | 24.38% |
| 2023 Q3 | 428.98 Million CNY | -28.5% |
| 2022 Q2 | 508.65 Million CNY | -12.12% |
| 2022 FY | - CNY | 16.46% |
| 2022 Q4 | 59.37 Million CNY | -83.44% |
| 2022 Q3 | 358.56 Million CNY | -29.51% |
| 2022 Q1 | 578.83 Million CNY | 781.07% |
| 2021 Q1 | 509.87 Million CNY | 77.88% |
| 2021 Q3 | 300.64 Million CNY | -19.46% |
| 2021 FY | - CNY | 44.78% |
| 2021 Q2 | 373.3 Million CNY | -26.78% |
| 2021 Q4 | 65.69 Million CNY | -78.15% |
| 2020 Q3 | 372.18 Million CNY | -14.02% |
| 2020 Q2 | 432.88 Million CNY | 9.8% |
| 2020 FY | - CNY | 49.2% |
| 2020 Q1 | 394.25 Million CNY | 116.77% |
| 2020 Q4 | 286.64 Million CNY | -22.98% |
| 2019 FY | - CNY | 27.26% |
| 2019 Q3 | 244.16 Million CNY | -14.7% |
| 2019 Q4 | 181.87 Million CNY | -25.51% |
| 2019 Q1 | 255.51 Million CNY | 45.66% |
| 2019 Q2 | 286.23 Million CNY | 12.02% |
| 2018 Q1 | 203.87 Million CNY | 37.56% |
| 2018 Q4 | 175.41 Million CNY | -1.71% |
| 2018 FY | - CNY | 16.87% |
| 2018 Q2 | 197.74 Million CNY | -3.0% |
| 2018 Q3 | 178.46 Million CNY | -9.75% |
| 2017 Q3 | 167.04 Million CNY | -2.82% |
| 2017 Q1 | 172.75 Million CNY | 44.58% |
| 2017 Q2 | 171.89 Million CNY | -0.5% |
| 2017 FY | - CNY | 13.94% |
| 2017 Q4 | 148.2 Million CNY | -11.28% |
| 2016 Q2 | 150.63 Million CNY | -11.1% |
| 2016 Q1 | 169.44 Million CNY | 0.0% |
| 2016 Q3 | 160.6 Million CNY | 6.61% |
| 2016 Q4 | 119.48 Million CNY | -25.6% |
| 2016 FY | - CNY | 6.27% |
| 2015 Q1 | 157.27 Million CNY | 0.0% |
| 2015 Q2 | 157.27 Million CNY | 0.0% |
| 2015 FY | - CNY | 25.55% |
| 2014 FY | - CNY | 41.11% |
| 2013 FY | - CNY | 30.35% |
| 2012 FY | - CNY | 0.0% |